Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Flexion Therapeutics IncFLXN · Entity 16545 | Chief Financial Officer | May 10, 2021 | May 12, 2021 |
| Seres Therapeutics, Inc.MCRB · Entity 7191 | Chief Financial Officer | February 14, 2024 | February 16, 2024 |
| iBio, Inc.IBIO · Entity 6906 | Director | November 20, 2025 | November 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Flexion Therapeutics Inc
Report date May 10, 2021 · Filed May 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 220,719 |
Reported balance
After 2021-05-10 transaction · row 1
1 source rowRow 1 · 2021-05-10 · Sale · Disposed 2,229 · Balance 220,719 F1: Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on June 1, 2018. F2: The weighted average sale price for the transaction reported was $7.23. The shares were sold at a range of prices between $7.14 and $7.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on June 1, 2018.
F2: The weighted average sale price for the transaction reported was $7.23. The shares were sold at a range of prices between $7.14 and $7.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Seres Therapeutics, Inc.
Report date February 14, 2024 · Filed February 16, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 182,442 |
Ending reported balance
After 2024-02-16 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-02-15 · Exercise / conversion · Acquired 10,625 · Balance 186,381 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Row 2 · 2024-02-16 · Sale · Disposed 3,939 · Balance 182,442 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F3: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2034-02-13 | Direct | 213,750 |
Reported balance
After 2024-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-14 · Grant · Acquired 213,750 · Balance 213,750 F4: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.10 · Expires 2034-02-13 | Direct | 287,905 |
Reported balance
After 2024-02-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-14 · Grant · Acquired 287,905 · Balance 287,905 F5: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 35,625 |
Reported balance
After 2024-02-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-14 · Grant · Acquired 35,625 · Balance 35,625 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F6: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 31,875 |
Reported balance
After 2024-02-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-15 · Exercise / conversion · Disposed 10,625 · Balance 31,875 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F3: The price reported in column 4 is a weighted average of the price. These shares were sold in multiple transactions at prices ranging from $1.08 to $1.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The option will vest as to 25% of the shares on February 14, 2025. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
F5: The option will vest, if at all, in two substantially equal installments upon achievement of a 30-day trailing average public market closing price per share of the Issuer's common stock greater than or equal to $3.00 and $5.00, respectively.
F6: The restricted stock units will vest and settle as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
F7: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
iBio, Inc.
Report date November 20, 2025 · Filed November 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.00 · Expires 2035-11-19 | Direct | 13,500 |
Reported balance
After 2025-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-11-20 · Grant · Acquired 13,500 · Balance 13,500 F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These options vest pro rata on a monthly basis over twelve months commencing on the date of the grant.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
F-star Therapeutics, Inc.
Report date November 20, 2020 · Filed March 09, 2023
Section 16 reporting ended · disclosed 2023-03-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-08 transaction · row 1
1 source rowRow 1 · 2023-03-08 · Other · Disposed 8,386 · Balance 0 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. F2: (Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.88 · Expires 2031-06-04 | Direct | 0 |
Reported balance
After 2023-03-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.41 · Expires 2032-06-17 | Direct | 0 |
Reported balance
After 2023-03-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)). F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option. F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.28 · Expires 2025-03-30 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-20 · Other · Disposed 10,000 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.05 · Expires 2026-07-27 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.27 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.99 · Expires 2028-06-17 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-20 · Other · Disposed 5,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.62 · Expires 2029-07-09 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-06-23 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-11-20 · Other · Disposed 7,500 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.79 · Expires 2021-11-23 | Direct | 0 |
Reported balance
After 2020-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-20 · Other · Disposed 4,386 · Balance 0 F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated June 22, 2022 (the "Merger Agreement"), by and among the Issuer, Sino Biopharmaceutical Limited, Fennec Acquisition Incorporated ("Parent"), and invoX Pharma Limited ("Purchaser"), including the completion on March 8, 2023 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $7.12 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 8, 2023. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
F2: (Continued from footnote 1) The number of shares of common stock reported reflects a one-for-four reverse stock split completed on November 20, 2020, and corrects the amount of shares of common stock previously reported by the Reporting Person in the Form 4 filed on January 2, 2020.
F3: Pursuant to the Merger Agreement, immediately prior to the Effective Time, each of the outstanding options that was otherwise eligible to vest in accordance with its terms was accelerated and became fully vested and exercisable immediately prior to, and contingent upon, the Effective Time (except in the case of the EMI Options (as defined in the Merger Agreement) granted pursuant to Rule 9.8 of the F-star Therapeutics, Inc. 2019 Equity Incentive Plan, which were accelerated and became fully vested and exercisable as of three business days prior to the Initial Expiration Date (as defined in the Merger Agreement)).
F4: As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that was less than the Offer Price (each, an "In the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Company Shares (as defined in the Merger Agreement) subject to such fully vested option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price over (B) the exercise price payable per Company Share under such option.
F5: (Continued from footnote 4) As of the Effective Time, by virtue of the Merger and without any further action on the part of the holders thereof, Parent, Purchaser or the Issuer, each option which had a per share exercise price that is equal to or more than the Offer Price (each, an "Out of the Money Option") that was then outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time without any consideration payable therefor. Any EMI Option that remained outstanding and unexercised as of immediately before the Effective Time was cancelled at the Effective Time and treated as either an In the Money Option or an Out of the Money Option.
F6: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020.
KINETA, INC./DE
Report date June 30, 2025 · Filed July 02, 2025
Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 1
1 source rowRow 1 · 2025-06-30 · Disposition to issuer · Disposed 16,571 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F3: The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022. F4: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-30 · Disposition to issuer · Disposed 12,500 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F5: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 | Direct | 0 |
Reported balance
After 2025-06-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-30 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement"). F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA. F5: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 11, 2024, by and among TuHURA Biosciences, Inc. ("TuHURA"), Hura Merger Sub I, Inc., a Delaware corporation and a direct wholly-owned subsidiary of TuHURA ("Merger Sub I"), Hura Merger Sub II, LLC, a Delaware limited liability company and direct wholly-owned subsidiary of TuHURA ("Merger Sub II,") and together with Merger Sub I, the "Merger Subs"), Kineta, Inc., a Delaware corporation ("Kineta") and Craig Philips, solely in his capacity as the representative, agent and attorney-in-fact of the stockholders of Kineta, and as amended by that certain First Amendment to Agreement and Plan of Merger, dated May 5, 2025 (as amended, the "Merger Agreement").
F2: This footnote is a continuation of footnote 1 above. Pursuant to the Merger Agreement, (i) Merger Sub I merged with and into Kineta (the "First Merger"), with Kineta surviving the First Merger as a wholly-owned subsidiary of TuHURA (the "Surviving Corporation"), and (ii) the Surviving Corporation merged with and into Merger Sub II (the "Second Merger" and together with the First Merger, the "Mergers"), with Merger Sub II surviving the Second Merger as a wholly-owned subsidiary of TuHURA.
F3: The number of shares of Kineta Common Stock held by the Reporting Person prior to the reported transaction has been updated to include the correct number of shares held by the Reporting Person following the merger between Kineta, Inc. and Yumanity Therapeutics, Inc., which closed on December 16, 2022.
F4: At the effective time of the First Merger (the "Effective Time"), each one (1) issued and outstanding share of Kineta's common stock, par value $0.001 per share ("Kineta Common Stock"), was cancelled and converted into the right to receive 0.185298 share of common stock of TuHURA, par value $0.001 per share ("TuHURA Common Stock"). Also pursuant to the Merger Agreement, each one (1) share of Kineta Common Stock is also entitled to (i) its pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months following the closing of the Mergers, subject to adjustment for losses incurred or accrued during the six month period from the closing of the Mergers, and (ii) the right to its pro rata share of cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets.
F5: At the Effective Time, each option to purchase shares of the Kineta Common Stock that was outstanding immediately prior to the Effective Time that had an exercise price per share greater than $0.64 was canceled and extinguished for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2020 Filed Mar 9, 2023 09:10 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherStock Option (right to buy) · Derivative | 5,500 | Not disclosed Strike: $9.05 | Not disclosed |
DisclosureSEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 5 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2026-07-27 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 20, 2020 Filed Mar 9, 2023 09:10 UTC | F-star Therapeutics, Inc. FSTX · Entity 115726 | OtherStock Option (right to buy) · Derivative | 10,000 | Not disclosed Strike: $9.28 | Not disclosed |
DisclosureSEC source: 0000899243-23-007654 · doc4.xml · derivative · entry 4 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-03-30 F6 · kind: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · price: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. F6 · derivative.exercise_date: Pursuant to the Share Exchange Agreement, dated as of July 29, 2020, these previously reported options and warrants were cancelled effective as of November 20, 2020. Read SEC document |
| November 19, 2020 Filed Nov 23, 2020 11:16 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | OtherWarrants · Derivative | 1,096 | $0.00 Strike: $43.16 | $0.00 |
DisclosureSEC source: 0000905718-20-001134 · springbank_fm4nov192020.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,096 shares Expires 2021-11-23 F1 · kind: The reported securities were called for redemption by the Issuer at their Black-Scholes value. Read SEC document |
| July 16, 2020 Filed Jul 20, 2020 21:33 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 38,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043120 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,121 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. 1/3 of the shares subject to the restricted stock unit award vest on each of July 16, 2021, July 16, 2022 and July 16, 2023. Read SEC document |
| June 29, 2020 Filed Jul 1, 2020 17:22 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 17,400 | $0.00 Strike: $1.39 | $0.00 |
DisclosureSEC source: 0001209191-20-039815 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,400 Underlying: Common Stock · 17,400 shares Expires 2030-06-29 F1 · derivative.exercise_date: These securities shall vest and become exercisable in equal quarterly installments starting on September 29, 2020 until the option is fully vested and exercisable on June 29, 2021, subject to the Reporting Person continuing to provide services to the Issuer. Read SEC document |
| June 24, 2020 Filed Jun 25, 2020 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001209191-20-038874 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-06-23 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 24, 2020, the date of the Issuer's 2020 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 16:21 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 1,303 | $10.83 | $14,111.49 |
DisclosureSEC source: 0001209191-20-038730 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,371 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 1,303 shares by the Reporting Person on June 22, 2020 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 07, 2020 Filed May 11, 2020 16:11 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 2,413 | $10.88 | $26,253.44 |
DisclosureSEC source: 0001209191-20-028249 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,068 F1 · kind: Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on June 1, 2018. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:14 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 15,500 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001209191-20-015120 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Underlying: Common Stock · 15,500 shares Expires 2030-03-01 F2 · derivative.exercise_date: Twenty-five percent (25%) of the shares shall vest on the one year anniversary of January 1, 2020 (the "Vesting Commencement Date") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 16:14 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015120 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,481 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 16:31 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 3,095 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-002279 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,481 F1 · kind: Sale of shares to cover tax withholding obligations associated with the vesting of a restricted stock unit award granted to the Reporting Person on March 1, 2019. F2 · price: The shares were sold at a range of prices between $19.76 and $19.91. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 31, 2019 Filed Jan 2, 2020 17:07 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 9,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000377 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,929 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document |
| September 30, 2019 Filed Oct 1, 2019 16:45 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 4,179 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-051312 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,831 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document |
| July 10, 2019 Filed Jul 11, 2019 08:52 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001209191-19-041762 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-07-09 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on July 10, 2019, the date of the Issuer's 2019 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 08:58 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 3,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039564 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,652 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to receive shares in lieu of cash compensation for services as a director and committee member. Read SEC document |
| June 21, 2019 Filed Jun 24, 2019 16:10 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 2,152 | $9.81 | $21,111.12 |
DisclosureSEC source: 0001209191-19-038758 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,576 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 2,152 shares by the Reporting Person on June 21, 2019 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| May 31, 2019 Filed Jun 3, 2019 16:18 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 2,500 | $11.05 | $27,626.75 |
DisclosureSEC source: 0001209191-19-033898 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,424 Read SEC document |
| May 13, 2019 Filed May 15, 2019 16:05 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 4,000 | $11.99 | $47,960.00 |
DisclosureSEC source: 0001209191-19-029970 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,924 F1 · price: The weighted average purchase price for the transaction reported was $11.99, and the range of prices were between $11.9877 and $11.9879. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| May 08, 2019 Filed May 9, 2019 16:32 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | SaleCommon Stock | 2,248 | $10.06 | $22,614.88 |
DisclosureSEC source: 0001209191-19-028497 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,924 F1 · kind: Sale of shares of common stock pursuant to Rule 10b5-1 arrangements to cover tax withholding obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on June 1, 2018. Read SEC document |
| March 29, 2019 Filed Apr 2, 2019 16:03 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-022328 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,756 F1 · kind: Pursuant to the Issuer's Non-Employee Director Compensation Policy, the shares on this Form 4 were automatically issued to the Reporting Person, who previously elected to take shares in lieu of cash compensation for services as a director and committee member of the Issuer. Read SEC document |
| March 06, 2019 Filed Mar 8, 2019 16:20 UTC | KINETA, INC./DE PTI · Entity 77778 | GrantStock Option (Right to Buy) · Derivative | 30,600 | $0.00 Strike: $4.07 | $0.00 |
DisclosureSEC source: 0001209191-19-018095 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,600 Underlying: Common Stock · 30,600 shares Expires 2029-03-06 F1 · derivative.exercise_date: These securities shall vest and become exercisable in equal quarterly installments starting on June 6, 2019 until the option is fully vested and exercisable on March 6, 2020, subject to continued service. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:27 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 18,000 | $0.00 Strike: $14.75 | $0.00 |
DisclosureSEC source: 0001209191-19-016498 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after January 1, 2019 (the "Vesting Commencement Date") and thereafter one-forty-eighth (1/48th) of the total shares shall vest each month following the one year anniversary of the Vesting Commencement Date, so that all of the shares shall be vested four (4) years after the Vesting Commencement Date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 16:27 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-016498 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,172 Read SEC document |
| December 20, 2018 Filed Jan 4, 2019 17:07 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | OtherCommon Stock | 922 | $10.48 | $9,662.56 |
DisclosureSEC source: 0001209191-19-002077 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,172 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 922 shares by the Reporting Person on December 20, 2018 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| November 09, 2018 Filed Nov 13, 2018 09:14 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 4,000 | $16.56 | $66,221.60 |
DisclosureSEC source: 0001209191-18-058085 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,250 F1 · price: The weighted average purchase price for the transaction reported was $16.5554, and the range of prices were between $16.5461 and $16.5595. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 09, 2018 Filed Aug 10, 2018 12:56 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | PurchaseCommon Stock | 4,000 | $23.42 | $93,680.00 |
DisclosureSEC source: 0001209191-18-046163 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,250 F1 · price: The weighted average purchase price for the transaction reported was $23.42, and the range of prices were between $23.3525 and $23.4288. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| June 18, 2018 Filed Jun 19, 2018 16:37 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $13.99 | $0.00 |
DisclosureSEC source: 0001209191-18-038574 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2028-06-17 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 18, 2018, the date of the Issuer's 2018 Annual Meeting of Stockholder, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 16:26 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 115,000 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0001209191-18-035083 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 115,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to the option shall vest one year after May 7, 2018; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of May 7, 2018, so that all of the shares subject to the option shall be vested four (4) years after May 7, 2018. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 16:26 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-035083 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,250 Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 16:02 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | PurchaseCommon Stock | 2,300 | $12.24 | $28,152.00 |
DisclosureSEC source: 0001209191-17-047862 · doc4.xml · nonDerivative · entry 2 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,386 Read SEC document |
| August 04, 2017 Filed Aug 7, 2017 16:02 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | PurchaseCommon Stock | 200 | $12.25 | $2,450.00 |
DisclosureSEC source: 0001209191-17-047862 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,086 Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 16:46 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantStock Option (right to buy) · Derivative | 5,500 | $0.00 Strike: $14.27 | $0.00 |
DisclosureSEC source: 0001209191-17-040557 · doc4.xml · derivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires 2027-06-14 F1 · derivative.exercise_date: Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 15, 2017, the date of the Issuer's 2017 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date. Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantWarrant (right to buy) · Derivative | 4,386 | $0.00 Strike: $10.79 | $0.00 |
DisclosureSEC source: 0000899243-16-034293 · doc4.xml · derivative · entry 2 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,386 Underlying: Common Stock · 4,386 shares Expires 2021-11-23 Read SEC document |
| November 23, 2016 Filed Nov 23, 2016 16:00 UTC | F-star Therapeutics, Inc. SBPH · Entity 115726 | GrantCommon Stock | 4,386 | $9.12 | $40,000.32 |
DisclosureSEC source: 0000899243-16-034293 · doc4.xml · nonDerivative · entry 1 Arkowitz David · CIK 0001296999 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,886 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.